Surgery Partners Take-Private at $23.50 Draws Law Firm Scrutiny

What happened

Shareholder rights firm Bleichmar Fonti & Auld announced an investigation into the proposed acquisition of Surgery Partners by Bon Secours Mercy Health at $23.50 per share. The offer represents a substantial premium to the stock's recent trading range, which had fallen to about $15.50 by late February 2026, a 38% decline from a year earlier. Our prior deep-value analysis had rated the stock a WAIT, with a base-case intrinsic value of $21 and a bull-case of $26, indicating the offer may undervalue the company if its operational turnaround succeeds. The law firm's investigation is a common tactic in mergers to assess whether the board fulfilled its fiduciary duty, and it does not by itself signal wrongdoing. Nevertheless, this development shifts the focus from operational execution to the fairness of the transaction price and process.

Implication

The merger offer provides a liquidity event at $23.50 per share, roughly 52% above the February 2026 low but still below our bull-case scenario of $26, suggesting potential value left on the table. Given Surgery Partners' high leverage, negative free cash flow in recent quarters, and execution risks, the offer may be attractive for risk-averse holders seeking certainty. However, the law firm investigation highlights the need for shareholders to independently assess whether the board negotiated the highest possible price, especially given the company's long-term upside if commercial payer mix recovers and debt is reduced. If the deal proceeds at the current price, it caps upside but eliminates downside; if the investigation uncovers conflicts or inadequate process, shareholders could push for a higher bid or challenge the deal. We recommend reviewing the merger proxy and staying alert for any competing offers before making a decision.

Thesis delta

The investment thesis shifts from a WAIT rating based on operational uncertainty to an event-driven assessment of the take-private price versus intrinsic value. The $23.50 offer exceeds our base case of $21 but falls short of the bull case of $26, making the negotiation process and potential conflicts a key risk. The law firm investigation introduces uncertainty about whether shareholders are receiving fair value, which could influence both deal completion and final terms.